- Home
- NCNA vs RNAZ Comparison
NCNA vs RNAZ Comparison
Compare NCNA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- RNAZ
- Stock Information
- Founded
- NCNA 1997
- RNAZ 2016
- Country
- NCNA United Kingdom
- RNAZ United States
- Employees
- NCNA N/A
- RNAZ N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- NCNA Health Care
- RNAZ Health Care
- Exchange
- NCNA Nasdaq
- RNAZ Nasdaq
- Market Cap
- NCNA 6.6M
- RNAZ 6.1M
- IPO Year
- NCNA 2017
- RNAZ 2021
- Fundamental
- Price
- NCNA $3.86
- RNAZ $10.70
- Analyst Decision
- NCNA
- RNAZ Strong Buy
- Analyst Count
- NCNA 0
- RNAZ 1
- Target Price
- NCNA N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- NCNA 338.4K
- RNAZ 11.5K
- Earning Date
- NCNA 08-20-2025
- RNAZ 08-14-2025
- Dividend Yield
- NCNA N/A
- RNAZ N/A
- EPS Growth
- NCNA N/A
- RNAZ N/A
- EPS
- NCNA N/A
- RNAZ N/A
- Revenue
- NCNA N/A
- RNAZ N/A
- Revenue This Year
- NCNA N/A
- RNAZ N/A
- Revenue Next Year
- NCNA N/A
- RNAZ N/A
- P/E Ratio
- NCNA N/A
- RNAZ N/A
- Revenue Growth
- NCNA N/A
- RNAZ N/A
- 52 Week Low
- NCNA $2.78
- RNAZ $6.15
- 52 Week High
- NCNA $1,650.00
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- NCNA 41.45
- RNAZ 51.67
- Support Level
- NCNA $2.82
- RNAZ $10.42
- Resistance Level
- NCNA $3.60
- RNAZ $11.45
- Average True Range (ATR)
- NCNA 0.24
- RNAZ 0.63
- MACD
- NCNA 0.43
- RNAZ 0.06
- Stochastic Oscillator
- NCNA 74.48
- RNAZ 65.28
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.